Atorvastatin Treatment in the Short Term: Does It Induce Renoprotection or Vasculoprotection in Renal Transplantation?

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2259-2263

  Navarro Munoz M ^a   Bonet, J ^a   Bayes B ^a   Lauzurica, R ^a   Blanco, S ^a   Romero, R ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; PULSE WAVE; RECIPIENT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RIGIDITY;

ADULT; AGED; BLOOD PRESSURE; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROTEINURIA; PYRROLES; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548696155     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.007     Document Type: Article

References (18)

1. Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today 11 (2006) 458
2. Manttari M., Tiula E., Alikoski T., et al. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26 (1995) 670
3. Agarwal R., and Curley T.M. The role of statins in chronic kidney disease. Am J Med Sci 330 (2005) 69
4. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426
5. Asberg A., Hartmann A., Fjeldsa E., et al. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 16 (2001) 1920
6. Mason J.C. The statins-therapeutic diversity in renal disease?. Curr Opin Nephrol Hypertens 14 (2005) 17
7. Calabro P., and Yeh E.T. The pleiotropic effects of statins. Curr Opin Cardiol 20 (2005) 541
8. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685
9. Kuipers H.F., Biesta P.J., Groothuis T.A., et al. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol 66 (2005) 653
10. Jandeleit-Dahm K., Cao Z., Cox A.J., et al. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 71 (1999) S31
11. Lentine K.L., and Brennan D.C. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant 19 (2004) 2378
12. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 suppl 7 (2004) 13
13. Bianchi S., Bigazzi R., Caiazza A., et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41 (2003) 565
14. Massy Z.A., and Guijarro C. Statins: effects beyond cholesterol lowering. Nephrol Dial Transplant 16 (2001) 1738
15. Kinlay S. Potential vascular benefits of statins. Am J Med 118 suppl 12A (2005) 62
16. Jones P., Kafonek S., Laurora I., et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582
17. Gupta S. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?. Int J Cardiol 96 (2004) 131
18. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071